119 results on '"Garralda E"'
Search Results
2. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)
3. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey
4. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
5. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
6. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
7. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
8. Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies
9. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey
10. 118O Definitive results for NSCLC and bladder cancer cohorts in the phase IIa trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial)
11. 127P Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors
12. 123P Pan-cancer homologous recombination deficiency (HRD) evaluation in patients enrolled in a routine molecular screening program
13. 223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST
14. 227TiP A phase II, open label, randomized, non-comparative cohorts study of adjuvant atezolizumab or atezolizumab plus tiragolumab in solid tumors with resectable disease with intermediate-high risk of recurrence and high tumor mutational burden (TMB-H) or microsatellite instability (MSI-H)
15. 1295P EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI
16. 1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
17. 680TiP A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
18. 664P Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
19. 656P Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
20. 624P Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
21. 616MO Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors
22. 614MO Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification
23. 607O Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors
24. 201P Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple-negative breast cancer (TNBC)
25. 173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors
26. 157P Phase I expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma
27. 6P Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials
28. 2314P Quality and safety of research biopsies (RB) in oncology clinical trials
29. 2246P Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
30. 2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
31. 1080TiP An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
32. 176P Enhancing immunotherapy response prediction via multimodal integration of radiology and pathology deep learning models
33. 1056P Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)
34. 1075TiP A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
35. 1074TiP A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
36. 1063P Differential tumor responses are a poor prognostic factor in patients receiving immune checkpoint inhibitors
37. 1048P Phase I/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer
38. 1045P Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
39. 1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
40. 1031P ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors
41. 1023MO Decoding immunotherapy resistance: A novel multiparametric magnetic resonance imaging approach to stratify cancer patient outcomes
42. 702P Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy
43. 695P A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
44. 672P Phase I/II trial of RVU120 (SEL120), CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
45. 538P Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials
46. 50 (PB040) - A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma
47. 7 Oral - Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors
48. 196 (PB076) - Non-invasive biomarkers for response and survival prediction in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICIs)
49. 137 (PB127) - Representation of young adult(19–29 y) and elderly(>75 y) patients populations in an early drug development unit
50. 133 (PB123) - Transition to the new EU CTIS Portal for Regulatory Clinical Trial Submissions: VHIO’s Start-Up Unit Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.